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Hyperkalemia is a common life-threatening problem in
hemodialysis patients. Because glycyrrhetinic acid (GA)
inhibits the enzyme 11b-hydroxy-steroid dehydrogenase II
and thereby increases cortisol availability to the colonic
mineralocorticoid receptor, it has the potential to lower
serum potassium concentrations. To test this, 10 patients
in a 6 month prospective, double-blind, placebo-controlled
crossover study were given cookies or bread rolls
supplemented with glycyrrhetinic acid or placebo. Twenty-
four-hour blood pressure measurements were performed at
baseline and week 6 and 12 of each treatment period. The
ratio of plasma cortisol/cortisone was significantly increased
in all patients on GA as compared to baseline or placebo,
indicating appropriate enzyme inhibition. Nine of the 10
patients had a persistent decrease in predialysis serum
potassium concentration. On GA, mean predialysis serum
potassium was significantly lower than at baseline or on
placebo. On placebo, serum potassium was significantly
elevated above the upper limit of normal in 76% compared
to 30% of measurements during GA treatment. Furthermore,
on this treatment the frequency of severe hyperkalemia
significantly decreased from 9% to 0.6%. No differences were
found in parameters reflecting sodium retention. Although
these studies show that prolonged GA supplementation
persistently lowers serum potassium in dialysis patients, a
long-term toxicity study will be mandatory before we
recommend the routine use of this treatment.
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Hyperkalemia is a common and sometimes life-threatening
problem in patients with end-stage renal disease and is a
frequent reason for emergency dialysis in patients undergoing
chronic renal replacement therapy.1 Severe hyperkalemia
(serum potassium 46.0 mmol/l) was reported to occur in
up to 12%2–4 of hemodialysis patients. In these patients,
three mechanisms account for hyperkalemia: an increase in
potassium intake, a decreased potassium excretion and a shift
of intracellular potassium to the extracellular fluid. Metabolic
acidosis, the main mechanism for intra–extracellular potas-
sium shift, is not a relevant cause of hyperkalemia at steady
state in adequately dialysed patients. The efficacy of a dietary
restriction of potassium intake as a measure to avoid
hyperkalemia is often limited for nutritional and compliance
reasons.1 In patients without renal function, the gastro-
intestinal excretion of potassium has a pivotal role.3,5 Thus,
pharmacological interventions enhancing the gastrointestinal
excretion of potassium are of potential relevance. The
gastrointestinal mode of disposal of potassium is enhanced
by cation exchange resins, together with a cathartic, usually
sorbitol.6 The efficacy of the unpleasant resin therapy has
been questioned7 and gastrointestinal side effects, including
colonic necrosis, have been observed.8,9 Thus, alternative
agents to enhance gastrointestinal potassium removal are
warranted.
Potassium secretion is an established mechanism of rectal
and colonic mucosa.10,11 This loss is regulated, at least in
part, by the mineralocorticoid receptor (MR).12 The activa-
tion of the MR by fludrocortisone enhances the rectal
electrical potential difference, an effect that is mimicked by
inhibiting the enzyme 11b-hydroxysteroid dehydrogenase
(11b-HSD2) in segments of normal rectal colon obtained
from humans.13
The 11b-HSD2 enzyme converts endogenous cortisol
into cortisone in mineralocorticoid target tissues including
epithelial cells of the colon.14,15 This mechanism protects the
MR from promiscuous activation by cortisol (Figure 1).16–18
Therefore, we hypothesize that inhibition of 11b-HSD2
might enhance intestinal potassium loss. In a 2-week prelimi-
nary proof of principle study, we showed that inhibition of
11b-HSD2 by glycyrrhetinic acid (GA), the active ingredient
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of licorice, decreased serum potassium concentrations in
patients on dialysis,19 an observation suggesting that this
xenobiotic has the potential to be a potassium-lowering agent
in dialysis patients. To determine the efficacy and safety of
GA, we designed a trial with a 3-month treatment period and
a 3-month placebo period.
RESULTS
Effect of GA on potassium concentrations in blood, urine, and
dialysate and on the serum ratios of cortisol/cortisone and
aldosterone/renin
Predialysis serum potassium concentrations were significantly
lower during periods with GA ingestion. In Figure 2 the values
obtained after 6 and 12 weeks on GA or placebo were
combined and compared with baseline measurements. Mean
observed serum potassium values were 5.5±0.6 mmol/l during
baseline, 4.4±0.6 mmol/l (week 6) and 4.6±0.6 mmol/l
(week 12), whereas on GA and 5.4±0.7 mmol/l (week 6)
and 5.3±0.7 mmol/l (week 12) during the placebo period.
Predialysis potassium concentrations during the GA period
were significantly lower when compared with the concentra-
tions at baseline or during the placebo periods (Po0.01 for
all). A combined linear model relating absolute individual
differences to drug exposure and time revealed a significant
difference in serum potassium concentrations between placebo
and GA (0.15±0.6 mmol/l and 0.95±0.45 mmol/l, respec-
tively, Po0.001) as compared with baseline values.
Of all the serum potassium measurements obtained
routinely before every dialysis session, 70% of the measure-
ments were in the defined normal range of 3.5–4.7 mmol/l
while patients were on GA, whereas only 24% were within
these limits in the placebo period (Po0.001, Table 1).
Furthermore, GA treatment reduced the frequency of severe
hyperkalemia (46 mmol/l) when compared with placebo
(0.6 vs 9%, Po0.001, Table 1). GA treatment induced a rapid
(within days) and sustained decline in predialysis serum
potassium concentrations (Figure 3). For the whole study
period, mean dialysate potassium concentrations were higher
on GA than on placebo (3.1±0.4 mmol/l vs 2.8±0.4 mmol/l,
Po0.05, Figure 3).
From 4 out of the 10 patients who dropped out during the
study at least one blood sample during the GA period was
obtained. When the predialysis serum potassium concentra-
tions of these samples were compared with those obtained at
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Figure 1 |Glucocorticoid receptors (GR) and mineralocorticoid
receptors (MR) are ligand-inducible transcription factors.
Following binding of steroid hormones these receptors
translocate from the cytoplasm into the nucleus and display
their transactivation potential. The intracellular concentrations
of steroid molecules available for binding to the cognate
receptor depends on the free extracellular concentrations and an
intracellular prereceptor control mechanism constituted by the
11 b-hydroxyglucocorticoid dehydrogenase (11 b-HSD) enzyme.
The 11b-HSD2 enzyme acts predominantly as a dehydrogenase
and converts 11b-hydroxyglucocorticoid cortisol with a high
affinity for both GR and MR into 11-ketosteroid cortisone with
virtually no affinity for MR or GR. By this mechanism the 11b-HSD2
enzyme protects MR from promiscuous activation by the
glucocorticoid hormone cortisol. Inhibition of the 11b-HSD2
enzyme by glycyrrhetinic acid (GA) increases cortisol
concentrations in MR-expressing cells and therefore causes a
glucocorticoid-mediated mineralocorticoid effect (from refs. 18
and 49).
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Figure 2 |Predialysis serum potassium concentrations at
baseline and during glycyrrhetinic acid (GA) and placebo
periods. The values displayed for the GA and placebo periods
represent the mean of the two measurements at weeks 6 and
12 on each treatment modality. Six patients (.) were on GA for
the first 12 weeks and then switched to placebo for 12 weeks,
whereas four patients (J) started with placebo and were
switched to GA. Potassium concentrations during GA
administration were lower than at baseline (**Po0.01) or during
intake of placebo (**Po0.01).
Table 1 | Predialysis serum potassium concentrations during
GA and placebo periods
GA
period
Placebo
period P-valuea
Measurements (n) 357 358
Within normal range (3.5–4.7mmol/l) 250 (70%) 84 (24%) o0.001
Hyperkalemia (46mmol/l) 2 (0.6%) 31 (9%) o0.001
Hypokalemia (o3.5mmol/l) 1 (0.3%) 1 (0.3%) NS
aFor GA period compared with placebo period. GA, glycyrrhetinic acid.
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baseline or during the placebo period, a uniform decline was
observed in all patients while on GA (5.7±0.4 mmol/l vs
4.5±0.3 mmol/l, Po0.01). Furthermore, no significant
changes in blood pressure or weight gain occurred during
the observation time (data shown below).
During the GA period, the ratio of plasma cortisol/
cortisone increased in all patients and was significantly
higher than at baseline or during the placebo phase of the
trial (Table 2). When these values were plotted against
the predialysis potassium concentrations given in Figure 2,
a significant inverse correlation (Po0.002) was found
(Figure 4). The increase in the cortisol/cortisone ratio
resulted from a uniform decrease in plasma cortisone in
the GA period (Table 2). Plasma aldosterone concentrations
and the aldosterone/renin ratios decreased significantly
during GA phases when compared with baseline and placebo
measurements (Table 2).
In an attempt to determine whether GA enhances urinary
potassium excretion, 24 h urine samples were obtained from
the day before dialysis at baseline and after 6 and 12 weeks on
each treatment modality. As expected, these values showed a
high variability among patients with some residual renal
function (baseline 46±39 mmol/24 h; GA 40±27 mmol/
24 h; placebo 43±30 mmol/24 h). The variability of urinary
sodium excretion was even more pronounced (baseline
97±113 mmol/24 h; GA 158±184 mmol/24 h; placebo
157±133 mmol/24 h).
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Figure 3 |Mean cumulative predialysis serum (J, K) and
dialysate (D) potassium concentrations. Each dot represents
the mean of all 10 patients at a given treatment session. A total of
357 measurements were performed during the GA and 358 during
the placebo period. The J and D with the bars represent
the mean (±s.d.) baseline serum and dialysate potassium
concentrations of the 10 patients. A sustained decrease in blood
potassium concentrations was observed 3–5 days after starting GA
treatment (K), and the concentrations in the dialysate increased
slightly (D) to avoid hypokalemia. When GA was discontinued,
potassium concentrations returned to baseline levels within 1
week. Blood potassium concentrations on GA were markedly
lower in the presence of higher dialysate potassium
concentrations (D) when compared with placebo. GA,
glycyrrhetinic acid.
Table 2 | Laboratory values at baseline, during glycyrrhetinic acid (GA) and placebo treatment
Baseline mean (±s.d.) GA mean (±s.d.) Placebo mean (±s.d.)
Cortisol (ng/ml) 101±25 116±38 102±56
Cortisone (ng/ml) 12.7±3 8.0±1.7** 11.2±3.2
Ratio cortisol/cortisone 8.1±2.1 14.3±3.3*** 9.7±3.3$$
Renin (ng/l) 18±18 23±14 27±22
Aldosterone (pmol/l) 1030±1539 356±301** 689±709$
Ratio aldosterone/renin 88.7±67 18±13** 37±36*
Sodium (mmol/l) 136±2.9 136±3.8 137±3.9
Bicarbonate (mmol/l) 23±2.6 23±1.4 23±2.6
Urea reduction rate (%) 74.7±4.3 75.8±5.5 77.5±4.3
Predialysis urea (mmol) 22.1±5.9 22.2±7.5 24.2±7.0
Alanine aminotransferase (U/l) 13±7 22±11* 14±8$
g-Glutamyl transpeptidase (U/l) 40±23 64±48* 46±51$
Parathyroid hormone (pg/ml) 234±177 219±122 217±174
1.25-OH-Vitamin D (pmol/l) 41±15 36±17 41±20
Fasting glucose (mmol/l) 5.9±1.4 5.5±1.2 6.1±1.8
Insulin (mmol/l) 16±23 12±16 18±21
Homeostatic Model Assessment Index 4.6±8 3.2±5 5.2±8
HbA1c (%) 4.8±0.6 6.1±0.9** 6.0±0.8*
Cholesterin (mmol/l) 4.2±0.9 3.8±0.7* 4.3±0.9
HDL (mmol/l) 1.6±0.5 1.6±0.5 1.6±0.5
Triglycerides (mmol/l) 1.6±1.2 1.6±1 1.7±1.1
Hemoglobin (g/l) 115±5.7 116±8.8 115±11.3
White cells (G/l) 6±1 6.9±3 6.4±1.4
Platelets (G/l) 221±84 239±89 220±70
Values presented in the GA and placebo columns represent the mean of the two measurements at week 6 and 12 on each modality.
*Po0.05 as compared with baseline measurements.
**Po0.01 as compared with baseline measurements.
***Po0.001 as compared with baseline measurements.
$Po0.05 as compared with GA period.
$$Po0.01 as compared with GA period.
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Side effects of GA
Mean pre- and post dialysis systolic/diastolic blood pressure
values were comparable on GA and placebo (142/66±
14/11 mm Hg vs 142/65±13/10 mm Hg and 137/66±
12/8 mm Hg vs 139/66±14/9 mm Hg, respectively). Simi-
larly, no differences were observed in the 24 h ambulatory
systolic and diastolic blood pressure measurements (baseline:
132/80±15/11 mm Hg; GA: 130/80±14/13 mmHg; placebo:
128/77±10/10 mm Hg). Mean 24 h ambulatory heart rate
was also unaffected by the treatment modality (70±13 vs
72±14 vs 71±14 b.p.m.).
Pre- and post dialysis weight as well as the interdialytic
weight gain, were assessed at every treatment session.
No significant differences were found in these parameters
when the GA period was compared with the placebo period
(predialysis weight: 76±15 kg vs 76±14 kg; interdialytic
weight gain: 2.02±0.63 kg vs 2.07±0.55 kg, respectively).
Orally administered GA was well tolerated in all patients
who concluded the trial. Reasons for dropout during the
study were mostly GA-unrelated and are given in the
Materials and Methods section. It is noteworthy that three
patients (two on GA, one on placebo) terminated the study
prematurely because of diarrhea (up to five bowel move-
ments/day in one patient on GA).
Although the HOMA index for insulin sensitivity tended
to be lower during GA treatment, HbA1c concentrations
increased during the GA and placebo periods (Table 2). Total
serum cholesterol concentrations were significantly reduced
during GA administration (Table 2). A moderate increase in
blood liver enzyme concentrations of ALAT and g-GT was
observed during the GA period (Table 2). Other serum and
hematology parameters were not influenced by GA (Table 2).
DISCUSSION
We show here that the potassium-lowering effect of GA in
patients with chronic renal failure persists for 3 months
without inducing hypertension or other relevant side effects.
In addition, GA appears to diminish the concentrations
of aldosterone, a steroid considered to be relevant for
myocardial fibrosis.
The mechanism underlying the uniform effect on serum
potassium concentrations with a clinically significant reduc-
tion of hyperkalemic episodes deserves some pathophysio-
logical considerations. Although a shift of potassium from
the extracellular to the intracellular compartment might be
a potential mechanism accounting for lowering serum
potassium concentrations during a short-term intervention,
as in our previous study,19 for mass balance reasons this
mechanism cannot explain the present diminished plasma
potassium levels lasting 3 months under steady-state
conditions. Furthermore, the main driving forces of such a
shift, that is, increased insulin concentrations or metabolic
acidosis, were not observed when patients were on GA. The
decline in serum potassium concentrations on GA is also not
explained by changes in dietary potassium intake because:
(i) predialytic and postdialytic weight did not change during
the study and dialysis prescriptions remained constant, and
(ii) predialytic parameters, including urea, phosphate,
bicarbonate, and creatinine concentrations, were not affected
by intake of GA. Thus, the most likely mechanism for the
diminished plasma potassium concentration is enhanced
extrarenal disposal. With respect to the anatomic site of
potassium loss, we can only speculate. It is possible that GA
enhanced rectal and colonic loss of potassium, most likely by
activation of the MR by hydrocortisone as a consequence
of the inhibition of 11b-HSD2 by GA.16,17 Alternatively, GA
might have modulated potassium loss by sweat.20
The effect of GA on 11b-HSD2 was reflected by an
increased ratio of cortisol/cortisone in all patients. Such an
inhibition of the gate-keeper enzyme of the MR allows
cortisol to bind to the MR and deploy a mineralocorticoid
action, which causes renal sodium retention, volume
overload and hypertension in humans with functioning
kidneys.17,18,21,22 Therefore, in this study, special attention
was paid to interdialytic weight gain and blood pressure
assessed by 24 h ambulatory and in-clinic pre- and post
dialysis recordings. Both body weight and blood pressure
were unaffected by GA. The observed absence of hyper-
tension is in line with previous studies where patients
were treated with the MR agonist fludrocortisone.23 It is
conceivable that an escape mechanism for sodium retention
is operative in the colonic epithelial cells, similar to that
observed in the kidney following prolonged administration
and/or secretion of aldosterone.24
Aldosterone and the serum aldosterone/renin ratio
decreased on administration of GA (Table 2), an effect
best explained by a diminished kalemia-related release of
aldosterone.25,26 A moderated release of aldosterone is of
potential clinical benefit as both the Randomized Aldactone
Evaluation Study27 and the Eplerenone Post-Acute Myo-
cardial Infarction Heart Failure Efficacy and Survival Study28
indicate that inhibition of aldosterone action by spirono-
lactone or eplerenone is beneficial in humans with heart
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Figure 4 |Relation between plasma cortisol/cortisone ratios
and predialysis serum potassium concentrations. A significant
(Po0.002) inverse correlation between cortisol/cortisone ratios
and serum potassium concentrations was found.
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failure. Although the mechanism of this beneficial effect of
aldosterone blockade in the Randomized Aldactone Evalua-
tion Study and Eplerenone Post-Acute Myocardial Infarction
Heart Failure Efficacy and Survival Study trials is still
debated, whether it is due to some genomic or non-genomic
effects of aldosterone,29 the concept that high aldosterone
concentrations induce cardiac hypertrophy and fibrosis
appears to be accepted knowledge.30 Thus, the present
observation of a decline of aldosterone concentrations after
GA dosing can be interpreted as a potentially beneficial effect.
However, cardiac fibrosis and hypertrophy are observed
when the MR is activated by aldosterone,31 and therefore
cardiac fibrosis is of concern when the MR is activated by
the glucocorticoid cortisol as a consequence of 11b-HSD2
inhibition (Figure 1). Because GA appears to show
antioxidative properties in various tissues including the
heart,32,33 and oxidative stress is a relevant mechanism in
MR activation-induced fibrosis, a GA effect blunting the
MR-induced fibrosis might exist. Although in our trial no
cardiac side effects have been observed, the issue of structural
heart damage by GA deserves further investigations.
Recent accumulating evidence from studies in animals and
humans suggest a potential beneficial effect of 11b-HSD1
inhibition on the metabolic syndrome.34 Because GA not
only inhibits 11b-HSD2, but also 11b-HSD1,35 the enzyme
catalyzing the transformation from inactive cortisone into
active cortisol, we investigated the effect of GA on glucose,
HbA1c, insulin-sensitivity and blood lipids. Surprisingly,
HbA1c increased slightly on both GA and placebo. The
reason for this increase is unknown. The number of cookies
(B50 g/d) or bread rolls (B30 g/d) consumed during both
study periods appears to be insufficient to explain this
increase. In line with previous investigations using a specific
11b-HSD1 inhibitor, insulin sensitivity (HOMA index)
tended to improve while the patients were taking GA.34,36
This is probably best explained by a diminished intracellular
ratio of biologically active 11b-hydroxyglucocorticoids to
inactive 11-keto-steroids.37
Previously, the mineralocorticoid hormone fludrocorti-
sone has been given to lower plasma potassium concentra-
tions in patients on hemodialysis.4,23,38–40 These studies were
unblinded and comprised no placebo group. Kaisar et al.4
compared prospectively patients with and without fludro-
cortisone for 3 months in an open-label trial and did not find
a significantly lower midweek predialysis serum potassium
concentration in patients on fludrocortisone. The dose of
fludrocortisone given in the latter study was lower than that
in the previous reports.23,38 Thus, the dose of fludrocortisone
showing a potential clinically relevant effect appears to be
unknown. If relatively high doses of fludrocortisone are
required in the future, side effects might be anticipated.
Fludrocortisone shows a 10 times higher glucocorticoid
potency than cortisol.41 Thus, systemic glucocorticoid effects
might appear especially in patients on dialysis because 80% of
fludrocortisone is recovered in urine following an oral or
intravenous dose in healthy normal volunteers.42 GA on the
other hand deploys its mineralocorticoid effects specifically
in MR-expressing target tissues, such as in the cortical
collecting duct or in the colonic epithelial cells, because the
MR-protecting enzyme 11b-HSD2 is selectively expressed in
cells with MR.16,17 The rigorous control of the 11b-HSD2
gene has recently been elucidated by our group and is at least
in part attributable to the presence of defined positive
regulatory components and differential methylation of CpG
islands in the promoter.43–46
The moderate increase of the serum liver enzymes
ASAT and g-GT when on GA indicates liver toxicity.
Interestingly, GA has been used in humans with hepatitis C
infection47,48 and animals with different liver toxicities as a
hepatoprotective agent.33 In this study, the increased liver
enzymes returned to baseline values during the placebo
period. Thus, a severe hepatotoxic effect of GA appears to be
unlikely. Nevertheless, the effect of GA on liver enzymes in
dialysis patients deserves further consideration in future
studies.
In conclusion, the present investigation indicates that the
long-term administration of GA to dialysis patients lowers
predialysis potassium concentrations and reduces the fre-
quency of dangerous hyperkalemic episodes without indu-
cing weight gain or hypertension. Before GA can be
recommended as a potassium-lowering agent, the pharma-
cokinetics and the chronic toxicity have to be evaluated
formally in dialysis patients.
MATERIALS AND METHODS
Study design and patients
The study was approved by the Ethics Committee of the University
of Berne, Switzerland and registered at www.clinicaltrial.gov (NCT
00384384). Based on an expected serum potassium concentration
decrease of 0.6±0.6 mmol/l during treatment with GA,19 a
minimum number of 10 patients was estimated to provide a
statistical power of 80%.
Twenty maintenance hemodialysis patients were randomly
allocated by a concealed randomization procedure to start either
with GA (n¼ 10) or placebo (n¼ 10) and enrolled in a prospective,
placebo-controlled 6 months crossover study (Figure 5). All patients
gave written informed consent. No patients with nephrotic
syndrome or cholestasis were included.49,50 Exclusion criteria were
age o18 years, dialysis vintage of less than 3 months, therapy with
glucocorticoids, insulin-treated diabetes mellitus and changes in
antihypertensive medication in the 2 weeks before inclusion. All
patients were asked to keep their fluid and dietary potassium intake
as constant as possible during the study period. Intake of licorice
and flavonoids were not allowed.21,51 Dropout reasons during the
study were: Death (one patient on placebo), kidney transplantation
(one patient on placebo), diarrhea (two patients on GA, one on
placebo), improvement of renal function with no further need of
dialysis (one patient on GA), hospitalization for low back pain (one
patient on placebo), withdrawal of consent (one patient on GA, one
on placebo), relocation (one patient on placebo). Ten patients
completed the study and were available for analysis. Patient
characteristics are shown in Table 3.
Blood samples were obtained at baseline and at week 6 and 12 of
the GA and the placebo period. All patients were dialyzed three
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times weekly. Blood samples were drawn before dialysis after the
long hemodialysis interval of 3 days and after 10 min supine rest.
Standard laboratory methods were used to determine sodium,
potassium, bicarbonate, creatinine, urea, liver enzymes, lipids,
parathyroid hormone (PTH), renin (substrate), insulin, glycosylated
hemoglobin (HbA1c), aldosterone, cortisol and cortisone at the
time points mentioned above. Moreover, serum potassium
concentrations were measured before each dialysis session with a
‘point of care’ AVL 988-4 device (AVL Medical Instruments,
Schaffhausen, Switzerland).
Pre- and post dialysis body weight and blood pressure
were recorded at every treatment session and oscillometric 24 h
ambulatory BP measurements (Profilomat II, Disetronic, Burgdorf,
Switzerland) were performed at baseline and week 6, 12, 18 and 24.
Administration of GA and placebo
Pharmaceutical quality 18-b-glycyrrhetinic acid dried powder
(Vital-Chem, Zhuhai, PR China, GMP Certificate number F0012,
Certificate of analysis/batch number JV050708) was administered
orally with permission from the Swiss authorities (Swissmedic).
According to the patients’ preference, either cookies or bread rolls
were supplemented with 500 mg GA or placebo (500 mg dextrose)
and given twice per day. Selection of this dose was based on the
results of our previously published pilot study.19 The cookies and
bread rolls were manufactured by our own hospital kitchen and
baked at a temperature of 80 1C (GA remains stable up to 160 1C).
Prescription of dialysis and antihypertensives
Intraindividual dialysis prescription parameters, including duration
of dialysis, blood flow, dialysate flow, conductivity and filter
were kept constant during the whole study period. Changes
in ultrafiltration rate and, if necessary, dialysate potassium
concentrations were allowed by protocol and registered for analysis.
All patients followed a conventional three times weekly dialysis
schedule. Dialysis dose was measured as equilibrated Kt/V (Kt/Ve)
and urea reduction rate (Table 2 and Table 3).
Prescription and dose alterations of ‘potassium-relevant’ drugs
(antihypertensives and exchange resins) are shown in Table 4.
Dosage of calcium channel blockers (given in 4 out of 10 patients)
was not changed, with the exception of one patient (No. 2) who
stopped 5 mg of amlodipine during the placebo period. The doses of
furosemide, a drug known to inhibit 11b-HSD in high doses, was
kept constant.52,53
Analysis of plasma cortisol and cortisone by gas
chromatography-mass spectrometry
2.5 mg of medroxyprogesterone (Steraloids, Newport, RI, USA) was
added to 0.75 ml of plasma as a recovery standard and the samples
were extracted with 10 ml of methylene chloride (Merck KGaA,
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Figure 5 |Patient recruitment and study flow schema.
Table 3 | Patient characteristics
Patient no. Sex Age
Renal
diagnosisa
Residual clearance
(ml/min)b
Residual urine
output (ml/24 h) Comorbiditiesc
Dialysis vintage
(months) Kt/Ve
1 F 78 1 2.5 1200 6 23 1.31
2 F 75 4 0 0 4 11 2.06
3 M 71 4 4.1 1800 7 56 1.44
4 M 81 2 1.3 400 5 51 1.48
5 M 54 3 0 0 4 91 1.35
6 F 73 2 1.8 400 5 56 1.35
7 M 73 4 5.7 1500 3 6 1.24
8 F 61 3 3.3 1500 5 4 1.34
9 M 81 4 0 0 4 66 1.36
10 F 68 3 0 0 7 18 1.53
a1 = diabetes, 2 = nephroangiosclerosis, 3 = glomerulonephritis, 4 = other or undefined.
bMeasured creatinine clearance (ml/min).
cCharlson comorbidity index.
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Darmstadt, Germany) on a rotator for 20 min. After centrifugation
at 3000 r.p.m. for 5 min, the two layers were separated and the
organic layer was transferred into a new tube. Methylene
chloride was evaporated under a stream of nitrogen at 45 1C.
Stigmasterol (Steraloids) was added as a standard for derivati-
zation and chromatography (2.5 mg in methanol). The solvent
was evaporated under nitrogen at 60 1C and the samples were
derivatized to form methyloxime–trimethylsilyl ethers. 100 ml of
methoxy amine hydrochloride 2% in pyridine (Pierce Biotechnology
Rockford, IL, USA) was added and the extracts were heated for
1 h at 60 1C for the formation of methyloximes. Pyridine was
evaporated under a stream of nitrogen at 60 1C, 100 ml of
trimethylsilyl imidazole (Pierce Biotechnology) was added and the
samples were heated at 100 1C for 16 h to form the trimethylsilyl
ethers. The derivatized steroids were purified by gel filtration on
Lipidex 5000 (Perkin Elmer Life and Analytical Sciences, Waltham,
MA, USA) columns.
The samples were analyzed by gas chromatography-mass
spectrometry using a gas chromatograph 6890N (Agilent, Santa
Clara, CA, USA) equipped with a mass selective detector 5973N
(Agilent) by selected ion monitoring during a temperature-
programmed run over 35 min. One characteristic ion was chosen
for each compound analyzed (m/z 605 for cortisol, m/z 531 for
cortisone, m/z 443 for medroxyprogesterone and m/z 394 for
stigmasterol). Calibration lines in the range of 5 to 500 ng were
established (correlation coefficient for cortisol was 0.9973, for
cortisone 0.9992).
Statistical analysis
All results are given as means±s.d., unless otherwise mentioned.
Statistical analyses were performed with the software packages
GraphPad 5 (GraphPad Software, La Jolla, CA, USA) and SAS 9.2
for Windows (The SAS Institute, Cary, NC, USA). Combined
general linear models were used to relate absolute differences from
baseline values of all the studied parameters to the time of
observation (6, 12, 18 or 24 weeks), to the drug exposure, and to
the patient studied. Student–Newman–Keuls tests were used for
comparison of means. The same modeling approach was used to
study changes in body weight, ultrafiltration, blood pressure and
point of care measurements of potassium available from each
dialysis session during the study. The interdialytic weight gain was
calculated by subtracting the post dialysis patient weight of the
previous dialysis from the actual predialysis weight. Addi-
tional statistical methods included Kruskal–Wallis, the two-sided
Mann–Whitney U-test for nonparametric analyses and Spearman’s
correlation.
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